Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter鈥檚 and Gitelman鈥檚 syndromes

详细信息    查看全文

• 作者：L. A. Cal貌 ; G. Maiolino
• 关键词：Rho kinase ; Nitric oxide ; Angiotensin II signaling ; Gitelman鈥檚 syndrome ; Bartter鈥檚 syndrome ; Hypertension ; Cardiovascular鈥搑enal remodeling
• 刊名：Journal of Endocrinological Investigation
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：38
• 期：7
• 页码：711-716
• 全文大小：
• 参考文献：1.Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119:524鈥?30PubMed Central PubMed CrossRef
  2.Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D (2004) Bartter鈥檚 and Gitelman鈥檚 syndromes: from gene to clinic. Nephron Physiol 96:65鈥?8CrossRef
  3.Cal貌 L, D鈥橝ngelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, Borsatti A (1996) Intracellular calcium signalling and vascular reactivity in Bartter鈥檚 syndrome. Nephron 72:570鈥?73PubMed CrossRef
  4.Cal貌 LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D鈥橝ngelo A, Pessina AC (2010) Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 28:111鈥?18PubMed CrossRef
  5.Cal貌 LA (2006) Vascular tone control in humans: insights from studies in Bartter鈥檚/Gitelman鈥檚 syndromes. Kidney Int 69:963鈥?66PubMed CrossRef
  6.Cal貌 LA, Davis PA, Rossi GP (2014) Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter鈥檚 and Gitelman鈥檚 syndromes, human models of endogenous angiotensin II signaling antagonism. J Hypertens 32:2109鈥?119PubMed CrossRef
  7.Cal貌 LA, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A (2001) Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 60:882鈥?89PubMed CrossRef
  8.Cal貌 LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A (2004) Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter鈥檚/Gitelman鈥檚 syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 89:4153鈥?157PubMed CrossRef
  9.Cal貌 LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, Pessina AC (2008) Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter鈥檚/Gitelman鈥檚 syndromes. J Hypertens 26:938鈥?45PubMed CrossRef
  10.Di Virgilio F, Cal貌 L, Cantaro S, Favaro S, Piccoli A, Borsatti A (1987) Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter鈥檚 syndrome. Clin Sci 72:483鈥?88PubMed
  11.Cal貌 L, D鈥橝ngelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, Borsatti A (1996) Intracellular calcium signalling and vascular reactivity in Bartter鈥檚 syndrome. Nephron 72:570鈥?73PubMed CrossRef
  12.Mehta PK, Griendling KK (2007) Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 92:C82鈥揅97
  13.Griendling KK, FitzGerald GA (2003) Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation 108:2034鈥?040PubMed CrossRef
  14.Cal貌 LA, Pagnin E, Davis PA, Sartori M, Semplicini A (2003) Oxidative stress related factors in Bartter鈥檚 and Gitelman鈥檚 sindrome: relevance for angiotensin II signaling. Nephrol Dial Transplant 18:1518鈥?525PubMed CrossRef
  15.Cal貌 LA, Facco M, Davis PA, Pagnin E, Maso LD, Puato M, Caielli P, Agostini C, Pessina AC (2011) Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res 34:1017鈥?022PubMed CrossRef
  16.Cal貌 LA, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, Zambon S, Cantaro S, D鈥橝ngelo A, Davis PA, Manzato E, Crepaldi G (1998) Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter鈥檚 and Gitelman鈥檚 sindrome). J Hypertens 16:1001鈥?008PubMed CrossRef
  17.Cal貌 L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, D鈥橝ngelo A (1999) Increased endothelial nitric oxide synthase mRNA level in Bartter鈥檚 and Gitelman鈥檚 syndrome. Relationship to vascular reactivity. Clin Nephrol 51:12鈥?7PubMed
  18.Cal貌 L, D鈥橝ngelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, Borsatti A (1996) Increased urinary NO2-/NO3- and cyclic GMP levels in patients with Bartter鈥檚 syndrome: relationship to vascular reactivity. Am J Kidney Dis 27:874鈥?79CrossRef
  19.Cal貌 LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P (2008) Absence of vascular remodelling in a high angiotensin-II state (Bartter鈥檚 and Gitelman鈥檚 syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 23:2804鈥?809PubMed CrossRef
  20.Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Cal貌 LA (2004) Rho kinase and PAI-1 in Bartter鈥檚/Gitelman鈥檚 syndromes: relationship to angiotensin II signaling. J Hypertens 22:1963鈥?969PubMed CrossRef
  21.Cal貌 LA, Pessina AC (2007) RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 25:259鈥?64PubMed CrossRef
  22.Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98:322鈥?24PubMed CrossRef
  23.Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P (2003) RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 278:9472鈥?480PubMed CrossRef
  24.Jin HG, Yamashita H, Nagano Y, Fukuba H, Hiji M, Ohtsuki T, Takahashi T, Kohriyama T, Kaibuchi K, Matsumoto M (2006) Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett 408:62鈥?7PubMed CrossRef
  25.Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effect on endothelial NAD(P)H oxidase system. Circ Res 93:767鈥?75PubMed CrossRef
  26.Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A (2002) Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39:245鈥?50PubMed CrossRef
  27.Pagnin E, Davis PA, Semplicini A, Cal貌 LA (2006) The search for a link between inflammation and hypertension鈥攃ontribution from Bartter鈥檚/Gitelman鈥檚 syndromes. Nephrol Dial Transplant 21:2340鈥?342PubMed CrossRef
  28.Sowers JR (2004) Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286:H1597鈥揌1602PubMed CrossRef
  29.Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, Kongo M, Kato S, Yamada N, Isaka N, Nakano T (2005) Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 25:2088鈥?093PubMed CrossRef
  30.Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK (2004) Inhibition of Rhokinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24:1842鈥?847PubMed Central PubMed CrossRef
  31.Wennerberg K, Der CJ (2004) Rho-family GTPases: it鈥檚 not only Rac and Rho (and I like it). J Cell Sci 117:1301鈥?312PubMed CrossRef
  32.Siderovski DP, Willard FS (2005) The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci 1:51鈥?6PubMed Central PubMed CrossRef
  33.Ying Z, Jin L, Dorrance AM, Webb RC (2004) Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 17:981鈥?85PubMed CrossRef
  34.Wuertz MC, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S (2010) p63RhoGEF鈥攁 key mediator of angiotensin II dependent signaling and processes in vascular smooth muscle cells. FASEB J 24:4865鈥?876PubMed CrossRef
  35.Momotani K, Artamonov MV, Utepbergenov D, Derewenda U, Derewenda ZS, Somlyo AV (2011) p63RhoGEF couples Gaq/11-mediated signaling to Ca2+sensitization of vascular smooth muscle contractility. Circ Res 109:993鈥?002PubMed Central PubMed CrossRef
  36.Guilluy C, Br茅geon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G (2010) The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 16:183鈥?90PubMed CrossRef
  37.Cal貌 LA, Davis PA, Pagnin E, Dal Maso L, Maiolino G, Seccia TM, Pessina AC, Rossi GP (2014) Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. Implications for vascular tone regulation and cardiovascular remodeling. J Hypertens 32:331鈥?38PubMed CrossRef
  38.Cal貌 LA, Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC (2005) Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. Arterioscler Thromb Vasc Biol 25:34鈥?5CrossRef
  39.Pagnin E, Semplicini A, Sartori M, Pessina AC, Cal貌 LA (2005) Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter鈥檚 and Gitelman鈥檚 syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens 18:1200鈥?205PubMed CrossRef
  40.Wirth A (2010) Rho kinase and hypertension. Biochim Biophys Acta 1802:1276鈥?284PubMed CrossRef
  41.Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM (2005) Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 23:1037鈥?045PubMed CrossRef
  42.Cal貌 LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P, Semplicini A, Palatini P, D鈥橝ngelo A, Pessina AC (2009) High angiotensin II state without cardiac remodeling (Bartter鈥檚 and Gitelman鈥檚 syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 32:832鈥?36PubMed CrossRef
  43.Carey RM (2005) Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45:840鈥?44PubMed CrossRef
  44.Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A, Cal貌 LA (2006) Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter鈥檚/Gitelman鈥檚 syndromes. Nephrol Dial Transplant 21:1697鈥?701PubMed CrossRef
  45.Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 62(Suppl. 82):12鈥?2CrossRef
  46.Cheng ZJ, Vapaatalo H, Mervaala E (2005) Angiotensin II and vascular inflammation. Med Sci Monit 11:RA194鈥揜A205PubMed
  47.Das UN (2005) Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit 11:155鈥?62
  48.Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, Kongo M, Kato S, Yamada N, Isaka N, Nakano T (2005) Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 25:2088鈥?093PubMed CrossRef
  49.Segain JP, Raingeard de la Bletiere D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP, Loirand G (2003) Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn鈥檚 disease and experimental colitis. Gastroenterology 124:1180鈥?187PubMed CrossRef
  50.Cal貌 LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC (2008) Linking inflammation and hypertension in humans: studies in Bartter鈥檚/Gitelman鈥檚 syndromes. J Hum Hypertens 22:223鈥?25PubMed CrossRef
  51.Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62:341鈥?54PubMed CrossRef
  
• 作者单位：L. A. Cal貌 (1)
  G. Maiolino (1)
  
  1. Department of Medicine, Nephrology and Hypertension, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy
  
• 刊物类别：Medicine/Public Health, general; Endocrinology; Metabolic Diseases;
• 刊物主题：Medicine/Public Health, general; Endocrinology; Metabolic Diseases;
• 出版者：Springer International Publishing
• ISSN：1720-8386

文摘

Introduction Extensive studies using Bartter鈥檚/Gitelman鈥檚 syndrome patients have provided insights into the angiotensin II (Ang II) signaling pathways involved in the regulation of vascular tone and cardiovascular鈥搑enal remodeling. The renin鈥揳ngiotensin鈥揳ldosterone system is activated in these syndromes, however, patients do not develop hypertension and cardiovascular remodeling and clinically manifest conditions opposite to hypertension. The short- and the long-term signaling of Ang II remains an important matter of investigation to shed light on mechanisms responsible for the pathophysiology of hypertension and its long-term complications. The long-term signaling of Ang II is involved in the pathophysiology of cardiovascular鈥搑enal remodeling and inflammatory responses in which the balance between RhoA/Rho kinase pathway and NO system plays a crucial role.